Vnitr Lek 2010, 56(10):1074-1077

Obesity and arterial hypertension

Ľ. Gašpar1,*, P. Poliak2, M. Makovník1, S. Hlinšťáková1, B. Krahulec1, T. Pišková1, M. Bendžala1
1 II. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta prof. MUDr. Andrej Dukát, CSc., FESC
2 I. anestéziologicko-resuscitačná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta MUDr. Juraj Koutun, CSc.

Obesity is an independent risk factor for the development and progression of hypertension, cardiovascular disease and chronic kidney disease. There is growing evidence that obesity and associated metabolic abnormalities may induce and accelerate renal complications in essential hypertension. The clustering of obesity and other features of the metabolic syndrome might have important implications for prevention, particularly with regard to whether interventions targeted at visceral obesity would have beneficial effects on cardiovascular and renal morbidity.

Keywords: obesity; arterial hypertension; metabolic syndrome; pathophysiological relationship

Received: June 13, 2010; Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gašpar Ľ, Poliak P, Makovník M, Hlinšťáková S, Krahulec B, Pišková T, Bendžala M. Obesity and arterial hypertension. Vnitr Lek. 2010;56(10):1074-1077.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Branca F, Nikogosian H, Lobstein T. The Challenge of Obesity in the WHO European Region and the Strategies for Response. World Health Organisation 2007. Available from: http://www.euro.who.int/document/E90711.pdf.
    2. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209. Go to original source... Go to PubMed...
    3. Narkiewicz K. Obesity and hypertension - the issue is more complex than we thought. Nephrol Dial Transplant 2006; 21: 264-267. Go to original source... Go to PubMed...
    4. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006; 38: 64-80. Go to original source... Go to PubMed...
    5. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profile and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005; 80: 1270-1277. Go to original source... Go to PubMed...
    6. Kastarinen MJ, Nissinen AM, Vartiainen EA et al. Blood pressure levels and obesity trends in hypertensive and normotensive Finnish population from 1982 to 1997. J Hypertens 2000; 18: 253-262. Go to original source... Go to PubMed...
    7. Krauss RM, Winston M, Fletcher RN et al. Obesity: impact on cardiovascular disease. Circulation 1998; 98: 1472-1476. Go to original source...
    8. Messerli FH, Christie B, DeCarvalho H et al. Obesity and essential hypertension: hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981; 141: 81-85. Go to original source...
    9. Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009; 32: 826-834. Go to original source... Go to PubMed...
    10. Jern S, Bergbrant JS, Bjöntorp K et al. Relation of central hemodynamics to obesity and body fat distribution. Hypertension 1992; 19: 520-527. Go to original source... Go to PubMed...
    11. Howell SJ, Sear JW, Foëx P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth 2004; 92: 570-583. Go to original source... Go to PubMed...
    12. Rahmouni K, Correia M, Haynes WG et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9-14. Go to original source... Go to PubMed...
    13. Redon J, Cifkova R, Laurent S et al. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008; 26: 1891-1900. Go to original source... Go to PubMed...
    14. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43: 518-524. Go to original source... Go to PubMed...
    15. Goodfriend TL, Ball DL, Egan BM et al. Epoxy-keto derivate of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43: 358-363. Go to original source... Go to PubMed...
    16. Carlyle M, Jones OB, Kuo JJ et al. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 2002; 39: 496-501. Go to original source... Go to PubMed...
    17. Marsh A, Fontes M, Killinger S et al. Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and dorsomedial hypothalamus. Hypertension 2003; 42: 488-493. Go to original source... Go to PubMed...
    18. da Silva AA, Kuo JJ, Hall JE. Role of hypothalamic melanocortin 3/4-receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension 2004; 43: 1312-1317. Go to original source... Go to PubMed...
    19. Fábryová Ľ. Vzťah viscerálnej obezity ku kardiometabolickým faktorom. Via pract 2008; 5: 122-125.
    20. Cardillo C, Campia U, Iantorno M et al. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004; 43: 36-40. Go to original source... Go to PubMed...
    21. Beltowski J, Wójcicka G, Marciniak A et al. Oxidative stress, nitric oxide production and renal sodium handling in leptin-induced hypertension. Life Sci 2004; 74: 2987-3000. Go to original source... Go to PubMed...
    22. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509. Go to original source... Go to PubMed...
    23. Keller G, Zimmer G, Mall G et al. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348: 101-108. Go to original source... Go to PubMed...
    24. Praga M, Hernández E, Herrero JC et al. Influence of obesity on the appearence of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000; 58: 2111-2118. Go to original source... Go to PubMed...
    25. Sin DD, Man SF. Impaired lung function and serum leptin in men and women with normal body weight: a population based study. Thorax 2003; 58: 695-698. Go to original source... Go to PubMed...
    26. Schünemann HJ, Dorn J, Grant BJ et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000; 118: 656-664. Go to original source... Go to PubMed...
    27. Nowbar S, Burkart KM, Gonzales R et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med 2004; 116: 1-7. Go to original source... Go to PubMed...
    28. Šimková I et al. Pľúcna hypertenzia očami kardiológa. Bratislala: SAP 2009.
    29. Julius S, Valentini M, Palatini P. Overweight and hypertension: a 2-way street? Hypertension 2000; 35: 807-813. Go to original source... Go to PubMed...
    30. Flegal KM, Graubard BI, Williamson DF et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298: 2028-2037. Go to original source... Go to PubMed...
    31. Svačina Š. Obezita a psychofarmaka. Praha: Triton 2002.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.